document-127417001

Status: The document is viewable through fallback artifacts while conversion repair continues in the background.

Queue: A repair attempt failed. The document remains flagged for retry and verification. (priority 90 · attempts 1 · next 2026-07-28 22:17:49)

Missing: html

Download: Source copy (xlsx) | pdf

2016-2017 Strategic Plan Objectives
Question 1: How Can I Recognize the Signs of ASD, and Why is Early
Detection So Important?
1.1. Strengthen the evidence base for the benefits of early detection of ASD.
1.2. Reduce disparities in early detection and access to services
1.3. Improve/validate existing, or develop new tools, methods, and service delivery models for
detecting ASD in order to facilitate timely linkage of individuals with ASD to early, targeted
interventions and supports.

Question 2: What Is the Biology Underlying ASD?
2.1. Foster research to better understand the processes of early development, molecular, and
neurodevelopmental mechanisms, and brain circuitry that contribute to the structural and functional
basis of ASD.
2.2. Support research to understand the underlying biology of co-occurring conditions in ASD and to
understand the relationship of these conditions to ASD.
2.3. Support large scale longitudinal studies that can answer questions about the development of ASD
from pregnancy through adulthood and the natural history of ASD across the lifespan.

Question 3: What Causes ASD, and Can Disabling Aspects of ASD be
Prevented or Preempted?
3.1. Strengthen understanding of genetic risk and resilience factors for ASD across the full diversity
and heterogeneity of those with ASD, enabling development of strategies for reducing disability and
co-occurring conditions in ASD.
3.2. Understand the effects on ASD risk and resilience of individual and multiple exposures in early
development, enabling development of strategies for reducing disability and co-occurring conditions
in ASD.
3.3. Expand knowledge about how multiple environmental and genetic risk and resilience factors
interact through specific biological mechanisms to manifest in ASD phenotypes.

Question 4: Which Treatments and Interventions Will Help?

4.1. Develop and improve pharmacological and medical interventions to address both core symptoms
and co-occuring conditions in ASD.
4.2. Create and improve psychosocial, developmental, and naturalistic interventions for the core
symptoms and co-occuring conditions in ASD.
4.3. Maximize the potential for technologies and development of technology-based interventions to
improve the lives of people on the autism spectrum.

Question 5: What Kinds of Services and Supports are Needed to Maximize
Quality of Life for People on the Autism Spectrum?
5.1. Scale up and implement evidence-based interventions in community settings.

5.2. Reduce disparities in access and in outcomes for underserved populations.

5.3. Improve service models to ensure consistency of care across many domains with the goal of
maximizing outcomes and improving the value that individuals get from services.

Question 6: How Can We Meet the Needs of People With ASD As They
Progress Into and Through Adulthood?
6.1. Support development and coordination of integrated services to help youth make a successful
transition to adulthood and continue to provide supports throughout the lifespan.
6.2. Support research and implement approaches to reduce disabling co-occurring physical and
mental health conditions in adults with ASD, with the goal of improving safety, reducing premature
mortality, and enhancing quality of life.
6.3. Support research, services activities, and outreach efforts that facilitate and incorporate
acceptance, accommodation, inclusion, independence, and integration of people on the autism
spectrum into society.

Question 7: How Do We Continue to Build, Expand, and Enhance the
Infrastructure System to Meet the Needs of the ASD Community?

7.1. Promote growth, integration, and coordination of the biorepository infrastructure.
7.2. Develop, enhance, and link the data repositories.

7.3. Expand and enhance the research and services workforce and accelerate the pipeline from
research to practice.
7.4. Strengthen ASD surveillance systems to further understanding of the population of individuals
with ASD, while allowing comparisons and linkages across systems as much as possible.

202X ASD Projects

Burden Statement: Public reporting burden for this collection of information is estimated to average 15 minutes per respo

* Please note that the use of the word 'response' in the Burden Statement refers to each individual project that is reporte
OMB# 0925-0682 Expiration: 1/31/2026
20XX ASD Research Spreadsheet
Organization Name
[FILL IN NAME]
20XX Total Funding

20XX Total Projects

For previously funded projects, please consider a project Ongoing if it received funding or ha
202X Project 202X Project Project Status Start Date (m End Date (mm/Multi-site (Ye Principal Invest

Enter all new 202X project inNew
Enter all new 202X project inNew

Page 4

202X ASD Projects

d to average 15 minutes per response*, including the time for reviewing instructions, searching existing data sources, gathering and main

h individual project that is reported, and not the data call in its entirety.

Ongoing if it received funding or had active research at any time in 202X.
Project Title Institution

State

Country

Page 5

Please provide a Weblink/url to a p

202X Funding 202X Funding Previous Webli

202X ASD Projects

g data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may

lease provide a Weblink/url to a project description. If a Weblink is unavailable, please provide a project description.

Previous ProjecNew or ReviseNew or RevisedPrevious SP Q Previous SP OSuggested 202X
Suggested
PA Question
202XCode
PA Objective
(BY AGENCY/O
Code

Page 6

202X ASD Projects

on of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of informatio

ject description.
Comments

Racial/Ethnic Disparities
OARC notes (inSubcategory Previous Subc (Y)

Page 7

202X ASD Projects

ond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burde

Page 8

202X ASD Projects

nd comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this

Page 9

202X ASD Projects

ding suggestions for reducing this burden, to: NIH, Project Clearance Branch, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892

Page 10

202X ASD Projects

kledge Drive, Bethesda, MD 20892-7983, ATTN: PRA (0925-0682*). Do not return the completed form to this address.

Page 11

202X ASD Projects
to this address.

Page 12

If you are aware of additional projects funded by your organization that may address a broader scientific scope bu
information in the rows below. The funding for these projects will not be included in your organization's total for
publicly available in the IACC Portfolio Analysis Report.
202X Project Number

Enter all new 202X
project information in
the adjacent cells

202X Project Number

Start Date
(mm/dd/yyyy)

End Date
(mm/dd/yyyy)

s a broader scientific scope but still have relevance to autism, please provide
n your organization's total for autism spending, but project details may be made

Principal Investigator

Project Title

Institution

State / Country

2019 Funding

Weblink

Project Description

Comments